IgA nephropathy

News

Otsuka eyes early filing of IgAN drug after phase 3 readout

Otsuka is hoping to file for approval of its anti-APRIL antibody sibeprenlimab as a treatment for kidney disorder IgA nephropathy (IgAN) after the drug hit the target in a phase 3 trial.

News

Novartis gets FDA OK for first in its trio of IgAN therapies

Novartis has claimed accelerated approval from the FDA for a second indication for Fabhalta – IgA nephropathy (IgAN) – as it charts a course to blockbuster sales for the drug.

News

Vertex wagers $4.9bn on Alpine kidney disease therapy

In another departure from its core focus on genetic medicines, Vertex Pharma has agreed a $4.9 billion purchase of Alpine Immune Sciences, adding a mid-stage drug candidat

News

CSL, Travere close on EU approval of IgAN drug sparsentan

Travere Therapeutics and partner CSL Vifor could be weeks away from EU approval of sparsentan for IgA nephropathy, after getting a positive opinion on the drug from the EM

News

Atrasentan data backs up Novartis’ $3.5bn Chinook deal

Novartis’ bid to build a strong presence in the treatment of rare kidney disease IgA nephropathy (IgAN) has been boosted by phase 3 data with atrasentan, the main asset in

News

Novartis adds another string to iptacopan’s bow

Novartis has another phase 3 trial win in its quiver for targeted factor B inhibitor iptacopan, building the case for the drug as a new oral therapy for diseases caused by

Otsuka eyes early filing of IgAN drug after phase 3 readout

Novartis gets FDA OK for first in its trio of IgAN therapies

Vertex wagers $4.9bn on Alpine kidney disease therapy

CSL, Travere close on EU approval of IgAN drug sparsentan

Atrasentan data backs up Novartis’ $3.5bn Chinook deal

Novartis adds another string to iptacopan’s bow

CHMP decision levels the playing field for GSK's RSV jab

How to meet your physicians where they are online

IgA nephropathy

Editor's Picks